These Analysts Boost Their Forecasts On Intuitive Surgical Following Strong Q4 Results

Intuitive Surgical Inc ISRG reported better-than-expected financial results for the fourth quarter after the market close on Thursday.

Intuitive Surgical reported fourth-quarter revenue of $2.41 billion, beating the consensus estimate of $2.25 billion. The robotic-assisted surgery company reported fourth-quarter adjusted earnings of $2.21 per share, beating analyst estimates of $1.79 per share, according to Benzinga Pro.

Intuitive Surgical expects full-year 2025 worldwide da Vinci procedures to increase approximately 13% to 16%. The company expects gross profit margin to be between 67% and 68% of net revenue in 2025.

"We are pleased with customer adoption of da Vinci 5, Ion, and SP during the quarter and full year. We remain focused on delivering the goals we share with our customers, centered on improving patient outcomes," Intuitive Surgical CEO Gary Guthart said in the preliminary release.

Intuitive Surgical shares fell 0.3% to close at $608.66 on Thursday.

These analysts made changes to their price targets on Intuitive Surgical following earnings announcement.

  • JP Morgan analyst Robbie Marcus maintained Intuitive Surgical with an Overweight rating and raised the price target from $575 to $675.
  • Citigroup analyst Joanne Wuensch maintained the stock with a Buy rating and boosted the price target from $640 to $711.

Considering buying ISRG stock? Here’s what analysts think:

Read This Next:

ISRG Logo
ISRGIntuitive Surgical Inc
$516.741.69%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
85.76
Growth
71.48
Quality
60.52
Value
9.91
Price Trend
Short
Medium
Long
Got Questions? Ask
Which healthcare stocks might follow ISRG's lead?
How will demand for robotic surgery evolve?
Which medical device companies stand to benefit from ISRG's growth?
Are there investment opportunities in surgical robotics?
How could rising da Vinci procedures impact ISRG's competition?
Which analysts' ratings could influence investor sentiment?
Could ISRG's performance affect healthcare ETFs?
How might profit margins impact future investments?
Which healthcare sectors could see increased investment?
What trends in patient outcomes are emerging post-ISRG announcement?
Market News and Data brought to you by Benzinga APIs
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise

Posted In:
Comments
Loading...